This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
NVAX Q1 Earnings Beat, Stock Jumps 16% on Matrix-M Deal Momentum
by Zacks Equity Research
Novavax's shares rise 16% after Q1 earnings beat estimates as the company expands Matrix-M partnerships across oncology and infectious diseases.
SNYNegative Net Change PFENegative Net Change NVAXNegative Net Change
biotechs earnings medical pharmaceuticals vaccines
Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook Maintained
by Zacks Equity Research
SRPT beats Q1 earnings and revenue estimates despite a sharp Elevidys sales drop, while maintaining its 2026 product revenue outlook.
RHHBYNegative Net Change SRPTNegative Net Change ARWRNegative Net Change
biotechs earnings gene-editing gene-therapy medical pharmaceuticals
CYTK Q1 Earnings Match Estimates, Revenues Beat on Myqorzo Launch
by Zacks Equity Research
Cytokinetics posts Q1 loss as Myqorzo launch lifts revenues to $19.4M, signaling commercial shift amid rising SG&A tied to rollout and expansion.
BMYNegative Net Change BAYRYNegative Net Change CYTKNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress Outlook
by Zacks Equity Research
Ocugen swings to a wider Q1 loss as costs climb, but pipeline milestones and gene therapy data keep its long-term plans on track.
CPRXPositive Net Change CSTLNegative Net Change OCGNNegative Net Change INDVNegative Net Change
biotechs
RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect
by Zacks Equity Research
Ultragenyx posts a wider-than-expected Q1 loss as Crysvita sales fall on seasonal effects, while Evkeeza and Dojolvi revenue growth partially offset declines.
REGNNegative Net Change CPRXPositive Net Change INOPositive Net Change RAREPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises
by Zacks Equity Research
ALKS beats Q1 estimates as strong proprietary drug sales lift revenues by 28%, sending shares higher, while Lumryz adds a fresh growth driver.
ALKSPositive Net Change AGENNegative Net Change AMRNNegative Net Change CSTLNegative Net Change
biotechs earnings
EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus
by Zacks Equity Research
EXEL beats Q1 EPS estimates on lower costs and buybacks but misses on revenues; Cabometyx sales lag estimates as pipeline progress and new buybacks stay in focus.
RHHBYNegative Net Change MRKNegative Net Change EXELNegative Net Change NTRAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Editas narrows Q1 loss as costs fall, but revenues drop sharply. Pipeline focus shifts to in vivo gene editing and lead candidate EDIT-401.
CPRXPositive Net Change EDITNegative Net Change CSTLNegative Net Change INDVNegative Net Change
biotechs
NVO Q1 Earnings & Sales Top Estimates, 2026 Outlook Raised, Stock Up
by Zacks Equity Research
Novo Nordisk stock jumps as Q1 earnings and revenues beat estimates, fueled by strong Wegovy and Ozempic demand and a raised 2026 outlook.
NVOPositive Net Change CPRXPositive Net Change INOPositive Net Change IMTXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Repligen's Q1 Earnings & Revenues Beat Estimates, Stock Rises
by Zacks Equity Research
RGEN tops Q1 earnings and revenue estimates, sending shares higher as strong chromatography and analytics business aid growth. The company raises its 2026 EPS view.
RGENPositive Net Change AGENNegative Net Change AMRNNegative Net Change CSTLNegative Net Change
biotechs earnings